Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL128759 | 0.92 | NPC1 (0.46) | L3MBTL1TSHRTDP1ALDH1A1CYP3A4 | |
| SCHEMBL16672914 | 0.88 | ALDH1A1 (0.60) | L3MBTL1TSHRTDP1ALDH1A1CYP3A4 | |
| SCHEMBL53331 | 0.85 | PPID (0.49) | L3MBTL1TSHRALDH1A1MAPK1NPC1 | |
| SCHEMBL23471179 | 0.84 | TSHR (0.55) | L3MBTL1TSHRTDP1ALDH1A1CYP3A4 | |
| SCHEMBL13259771 | 0.84 | ALDH1A1 (0.66) | L3MBTL1TSHRTDP1ALDH1A1CYP3A4 | |
| SCHEMBL11525397 | 0.84 | ALDH1A1 (0.58) | L3MBTL1TSHRTDP1ALDH1A1MAPK1 | |
| SCHEMBL23471317 | 0.83 | TSHR (0.54) | L3MBTL1TSHRTDP1ALDH1A1CYP3A4 | |
| SCHEMBL2042795 | 0.83 | PPID (0.47) | L3MBTL1ALDH1A1MAPK1NPC1RAB9A | |
| SCHEMBL8979745 | 0.81 | NPC1 (0.47) | L3MBTL1TSHRTDP1ALDH1A1CYP3A4 | |
| SCHEMBL16673251 | 0.81 | TDP1 (0.58) | L3MBTL1TSHRTDP1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1277748-B1 | Process for producing optically active y-Butyrolactone | TAKASAGO PERFUMERY CO LTD (JP) | 2004-04-21 | — | — | EP | disclosed |
| EP-1403262-A1 | Process for producing optically active alpha butyrolactone | Takasago International Corporation (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-6608214-B2 | Hydrogenating optically active 4-substituted oxy-3-hydroxy-butyrate followed by simultaneous deprotection and ring closure; economic and efficient synthesis | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-08-19 | — | — | US | disclosed |
| US-20030105341-A1 | Process for producing optically active gamma-butyrolactone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-06-05 | — | — | US | disclosed |
| EP-1277748-A1 | Process for producing optically active y-Butyrolactone | Takasago International Corporation (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-4421922-A | Process for the production of tetronic acid | LONZA LTD. (CH) | 1983-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105341-A1 | Process for producing optically active gamma-butyrolactone | HSD17B10, HSD17B1, HSD17B12 | L3MBTL1 3136/4885TSHR 4191/4885TDP1 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.